



# Guidelines on autopsy practice

## Fetal autopsy of 2nd trimester fetal loss (excluding termination of pregnancy for congenital anomaly)

**DRAFT February 2024**

**Series authors:** Dr Esther Youd, Clinical Lead for Autopsy Guidelines  
Dr Ben Swift, Forensic Pathology Services, Oxon

**Specialist authors:** Dr Tamas Marton, Birmingham Women's and Children's Hospital NHS Foundation Trust  
Dr Beata Hargitai, Birmingham Women's and Children's Hospital NHS Foundation Trust  
Dr Flora Jessop, Cambridge University Hospitals NHS Foundation Trust  
Dr J Ciaran Hutchinson, Great Ormond Street Hospital NHS Foundation Trust  
Professor Christoph Lees, Imperial College Healthcare NHS Trust  
Dr Tracey Johnston, Birmingham Women's and Children's Hospital NHS Foundation Trust

<b>Unique document number</b>	G161
<b>Document name</b>	Guidelines on autopsy practice: Fetal autopsy of 2nd trimester fetal loss (excluding termination of pregnancy for congenital anomaly)
<b>Version number</b>	V2
<b>Produced by</b>	The specialist content of this guideline has been produced by: Dr Tamas Marton MD, FRCPath, PhD, Consultant Perinatal Pathologist, Birmingham Women's and Children's Hospital Foundation Trust and Department of Obstetrics and Gynaecology, Semmelweis University, Faculty of Medicine; and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary



	<p>Dr Beata Hargitai, MD, Affiliate Member of RCPATH, PhD, Consultant Perinatal Pathologist, Birmingham Women's and Children's Hospital Foundation Trust and Department of Obstetrics and Gynaecology, Semmelweis University, Faculty of Medicine; and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary</p> <p>Dr Flora Jessop, Cambridge University Hospitals NHS Foundation Trust</p> <p>Dr Ciaran Hutchinson, Great Ormond Street Hospital NHS Foundation Trust</p> <p>Professor Christoph Lees, Imperial College Healthcare NHS Trust</p> <p>Dr Tracey Johnston, MD, FRCOG, Birmingham Women's and Children's Hospital NHS Foundation Trust</p>
<b>Date active</b>	February 2024
<b>Date for full review</b>	February 2029
<b>Comments</b>	<p>This document will replace the 1st edition of the <i>Guidelines on autopsy practice: Fetal autopsy (2nd trimester fetal loss and termination of pregnancy for congenital anomaly)</i>, published in June 2017.</p> <p>In accordance with the College's pre-publications policy, this document will be on the Royal College of Pathologists' website for consultation from 28 February to 27 March 2024. Responses and authors' comments will be available to view on publication of the final document.</p> <p><b>Dr Brian Rous</b> <b>Clinical Lead for Guideline Review</b></p>

The Royal College of Pathologists  
6 Alie Street, London E1 8QT  
Tel: 020 7451 6700  
Fax: 020 7451 6701  
Web: [www.rcpath.org](http://www.rcpath.org)

Registered charity in England and Wales, no. 261035  
© 2024, the Royal College of Pathologists

This work is copyright. You may download, display, print and reproduce this document for your personal, non-commercial use. Requests and inquiries concerning reproduction and rights should be addressed to The Royal College of Pathologists at the above address. First published: 2024.

# Contents

Foreword.....	4
1 Introduction.....	6
2 The role of the autopsy.....	8
3 Consent.....	8
4 Clinical information relevant to the autopsy .....	9
5 The autopsy procedure .....	10
6 Specific health and safety aspects .....	13
7 Focused autopsy: limited by parental consent or by a stepwise post-mortem examination .....	13
8 Sampling at full post-mortem examination.....	14
9 Autopsy report.....	14
10 Coding.....	16
11 Criteria for audit.....	17
12 References.....	19
Appendix A Suggested flowchart of a triage approach .....	21
Appendix B Sample autopsy request form.....	22
Appendix C Autopsy-related SNOMED CT codes .....	26
Appendix D Summary table – Explanation of grades of evidence.....	28
Appendix E AGREE II guideline monitoring sheet.....	29



NICE has accredited the process used by the Royal College of Pathologists to produce its guidelines. Accreditation is valid for 5 years from 25 July 2017. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## Foreword

The autopsy guidelines published by the Royal College of Pathologists (RCPATH) are guidelines which enable pathologists to deal with non-forensic consent, coroner's and procurator fiscal post-mortem examinations in a consistent manner and to a high standard. They are intended primarily for the profession; some technical content may be distressing for the lay audience.

The guidelines are systematically developed statements to assist the decisions of practitioners and are based on the best available evidence at the time the document was prepared. Given that much autopsy work is single observer and one-time only in reality, it has to be recognised that there is no reviewable standard that is mandated beyond that of the FRCPath Part 2 exam or the Certificate of Higher Autopsy Training (CHAT).

Nevertheless, much of this can be reviewed against ante-mortem imaging and other data. This guideline has been developed to cover most common circumstances. However, we recognise that guidelines cannot anticipate every pathological specimen type and clinical scenario. Occasional variation from the practice recommended in this guideline may therefore be required to report a specimen in a way that maximises benefit to the pathologist, coroner/procurator fiscal and the deceased's family.

At the time of drafting these guidelines, there is some uncertainty around workflow and the optimisation of patient pathways, despite great efforts by regional units to maintain service provision. Relevant additional material, including a parent pathway, is being drafted by NHS England, which aims to optimise the pathway and experience for parents at what is a very difficult time. Timely communication with parents via appropriate channels is critical to providing status updates regarding the examination and its findings, and providing answers for families experiencing great distress. Reference to these materials should be made, where required.

There is a general requirement from the General Medical Council (GMC) to have continuing professional development (CPD) in all practice areas and this will naturally encompass autopsy practice. Those wishing to develop expertise/specialise in pathology are encouraged to seek appropriate educational opportunities and participate in the relevant external quality assurance (EQA) scheme.

The guidelines themselves constitute the tools for implementation and dissemination of good practice.

The stakeholders consulted for this document were:

- British and Irish Paediatric Pathology Association (BRIPPA)
- Stillbirth and Neonatal Death Charity (Sands)
- The Royal College of Obstetrics and Gynaecologists (RCOG)
- Antenatal Results and Choices (ARC)
- Miscarriage Association
- Human Tissue Authority (HTA)
- The Coroners' Society of England and Wales
- Crown Office and Procurator Fiscal Service (COPFS) Scotland
- Coroner's Service for Northern Ireland
- The Home Office Forensic Science Regulation Unit and Forensic Pathology Unit and the British Medical Association
- Pregnancy and Baby Charities Network.

The information used to develop this document was derived from current medical literature and a previous version of this guideline. Much of the content of the document represents custom and practice and is based on the substantial clinical experience of the authors. All evidence included in this guideline has been graded using modified SIGN guidance (see Appendix D). The sections of this autopsy guideline that indicate compliance with each of the AGREE II standards are indicated in Appendix E.

No major organisational changes or cost implications have been identified that would hinder the implementation of the guidelines.

A formal revision cycle for all guidelines takes place on a 5-year cycle. The College will ask the authors of the guideline to consider whether or not the guideline needs to be revised. A full consultation process will be undertaken if major revisions are required. If minor revisions or changes are required, a short note of the proposed changes will be placed on the College website for 2 weeks for members' attention. If members do not object to the changes, the changes will be incorporated into the guideline and the full revised version (incorporating the changes) will replace the existing version on the College website.

The guideline has been reviewed by the Professional Guidelines team, Death Investigation Committee, Forensic Pathology Specialty Advisory Committee and Lay Advisory Group. It will be placed on the College website for consultation with the membership from 28 February to 27 March 2024. All comments received from the membership will be addressed by the author to the satisfaction of the Clinical Lead for Guideline Review.

This guideline was developed without external funding to the writing group. The College requires the authors of guidelines to provide a list of potential conflicts of interest; these are monitored by the Professional Guidelines team and are available on request. The authors of this document have declared that there are no conflicts of interest.

## 1 Introduction

This guideline is review of the previous *G161 Guidelines on autopsy practice Fetal autopsy (2nd trimester fetal loss and termination of pregnancy for congenital anomaly)*.

The most important change to the previous perinatal autopsy guidelines is that previous guidelines titled *G160 Guidelines on autopsy practice: Third trimester antepartum and intrapartum stillbirth* and *G161 Guidelines on autopsy practice: Fetal autopsy (2nd trimester fetal loss and termination of pregnancy for congenital anomaly)* were gestational age based and addressed the autopsy of both malformed and non-malformed fetuses, including termination of pregnancy for developmental abnormality. During the review of the fetal autopsy series, 3 guidelines were developed to cover perinatal post mortems. The new guideline addresses the malformed fetuses of any gestational age with particular focus on the new diagnostic modalities.

The following post-mortem guidelines are the new titles published in the fetal perinatal autopsy series:

- *G160 – Guidelines on autopsy practice: Fetal autopsy following antepartum or intrapartum death of non-malformed fetuses*
- *G161 – Guidelines on autopsy practice: Fetal autopsy of 2nd trimester fetal loss (excluding termination of pregnancy for congenital anomaly)*
- *G193 – Guidelines on autopsy practice: Fetal autopsy after termination of pregnancy for congenital anomaly.*

1 Post-mortem examination of a baby following spontaneous or missed miscarriage in the  
2 second trimester (12+0–23+6 weeks gestation) may provide a complete or partial  
3 explanation of the pregnancy loss.<sup>1,2</sup>

4 The voice of bereaved parents has been central to producing these guidelines. Many  
5 bereaved parents want to access a post-mortem examination for their baby, seeking the  
6 possibility of answers, even if only to rule out some underlying conditions rather than elicit  
7 specific positive findings. Bereaved parents have told us that the post mortem can become  
8 an important part of their path through their grief. The post-mortem report can support  
9 difficult decisions about another pregnancy. It is, of course, extremely common for parents  
10 to feel protective and strongly connected to their baby – the acute sensitivities and  
11 emotional context make perinatal post mortem unlike any other investigative procedure.  
12 The report authors have held the narrative of parents' vulnerabilities and wishes at the  
13 heart of the discussions involved in producing these guidelines.

14 This guideline has been created to assist the pathologist undertaking autopsies in cases of  
15 second trimester (late) miscarriage AND second trimester intrauterine death (missed  
16 miscarriage). It provides an outline of the clinical presentations where a fetal autopsy may  
17 be beneficial, practical technical advice on performing the autopsy, guidance on the use of  
18 additional investigations and minimum standards for the content of the autopsy report. It is  
19 intended as a guide to reasonable practice, rather than a policy statement. Where  
20 possible, strong parental preferences (as documented on the consent form or in the  
21 referral documentation) should be taking into consideration by the responsible consultant.

22 In England, Wales and Northern Ireland, autopsy facilities and procedures must be  
23 covered by appropriate licences issued by the HTA and consent procedures must be  
24 compliant with the relevant HTA Code of Practice. Separate legislation applies in Scotland,  
25 which does not impose a system of licensing.

## 26 **1.1 Target users of this guideline**

27 The target primary users of this guideline are UK consultant and trainee  
28 perinatal/paediatric pathologists. The recommendations will also be of value to  
29 pathologists working outside the UK, obstetricians (including fetal medicine specialists),  
30 neonatal paediatricians, anatomical pathology technologists (APTs) and bereavement  
31 midwives.

32

## 2 The role of the autopsy

The role of the autopsy on fetuses in the second trimester is to:

- establish the cause and/or the mechanism of fetal death
- identify concomitant diseases, and fetal, maternal and placental conditions, particularly those with implications for subsequent pregnancies (e.g. fetal growth restriction, malformation, fetal effects of maternal diabetes)
- identify evidence of genetic disease and assist determination of the likely recurrence risk.

The post-mortem report should:

- support pathology input into local perinatal mortality review meetings
- provide information for audit purposes (e.g. antenatal diagnosis, pregnancy and intrapartum care, Perinatal Mortality Review Tool [PMRT])
- provide information for national clinical outcome review programmes, e.g. MBRRACE-UK.

## 3 Consent

Consent must always be obtained for the hospital post-mortem examination of a baby, whether born alive or dead, and at any gestation.

Consent is also required for all genetic testing, including of placental samples. Local protocols should be established between clinical genetics and histopathology departments.

This will help to ensure that appropriate consent is in place prior to the release of tissue for any genomic investigation.

The only time when parental consent/authorisation for a post-mortem examination on a baby is not needed is when a coroner or procurator fiscal orders a post-mortem examination; this is unlikely to be relevant in the clinical context of these guidelines.

Regardless of the gestation, perinatal post-mortem examination may only be performed if informed consent has been given by the mother, unless there are exceptional circumstances, e.g. if she is too ill to consent. Wherever possible, in this situation, the partner's consent/authorisation should also be sought.<sup>3</sup>



1 The consent process should be compliant with the requirements of the HTA's Code of  
2 Practice: Code A: Guiding Principles and the Fundamental Principle of Consent.<sup>4</sup>

3 In Scotland, Human Tissue (Scotland) Act 2006 is in force and the consent process should  
4 follow the legislation.<sup>5</sup>

5 The autopsy consent form should be compliant with the model 'Consent form for perinatal  
6 post mortem' developed by Sands, in conjunction with the HTA.

7 The pathologist performing the autopsy must see the completed consent form, either as a  
8 physical copy or electronically, before commencing the autopsy. Any limitations on the  
9 scope of the autopsy must be complied with.

10 Any concerns regarding the validity of the consent should be resolved before commencing  
11 the autopsy.

12 The consent form indicates the maximal extent of the post-mortem examination that  
13 should be performed. For some patients, if the responsible consultant considers that a  
14 more limited examination can adequately answer the questions raised, the examination  
15 may not include some of the components, in keeping with the latest NHS guidance.<sup>6</sup> This  
16 depends on the specific features and history for each patient and is at the discretion of the  
17 consultant pathologist responsible for the examination.

18 *[Level of evidence GPP – in line with statutory obligations.]*

## 19 **4 Clinical information relevant to the autopsy**

20 The relevant clinical information (best obtained using structured request form, see  
21 Appendix A) includes:

- 22 • patient identification details
- 23 • maternal age/date of birth
- 24 • maternal height, weight and BMI
- 25 • relevant medical and family history, including consanguinity
- 26 • obstetric history, previous pregnancies/deliveries, including previous fetal and neonatal  
27 losses (if post-mortem examination had been carried out), malformation and growth  
28 restriction and other complications

29

- 1 • history of current pregnancy, including:
  - 2 – estimated delivery date (gestation by date and by scan)
  - 3 – antenatal infection screen results, including cytomegalovirus, toxoplasma, HIV
  - 4 – abnormal findings from ultrasound or other antenatal investigations (copy of the
  - 5 ultrasound report is highly desirable, mandatory with antenatally diagnosed
  - 6 structural abnormalities)
  - 7 – cervical length measurements of the uterus if undertaken and information about
  - 8 cervical cerclage
  - 9 – any concerns regarding fetal growth/fetal monitoring including Doppler
  - 10 investigations of the maternal and fetal circulations
  - 11 – results of first trimester screening, non-invasive tests, chorion villous sample (CVS)
  - 12 and amniocentesis
  - 13 – the presence of complications, such as pregnancy-induced
  - 14 hypertension/preeclamptic toxemia
  - 15 – events leading up to intrauterine death and/or delivery (membrane rupture, maternal
  - 16 pyrexia, antenatal bleeding, last evidence of fetal heartbeat).

17 [Level of evidence – B.]

## 19 **5 The autopsy procedure**

20 This guideline refers specifically to second trimester pregnancy losses (spontaneous or  
21 missed miscarriage). Pregnancy loss may occur prior to, or after, the anomaly (mid-  
22 trimester) scan. The approach to the autopsy differs depending on whether this has  
23 occurred, and the result of the scan.

- 24 a) If the pregnancy loss occurs before the mid-trimester anomaly scan, or the scan could  
25 not be completed for any reason, full post-mortem examination is recommended to  
26 check the anatomical structures, where consent has been provided.
- 27 b) If the scan identified structural abnormalities, and the pregnancy ends spontaneously  
28 (i.e. miscarriage or intrauterine fetal death), the protocol for ‘termination of pregnancy  
29 for congenital anomaly’ should be followed to ensure full assessment for congenital  
30 abnormality.

- 1 c) If gross examination reveals structural abnormalities, the protocol for 'termination of  
2 pregnancy for congenital anomaly' should be followed.
- 3 d) If pregnancy loss occurred after a negative anomaly scan, and the baby proves to be  
4 non-dysmorphic at external examination, yield from an invasive post-mortem  
5 examination is likely to be low.<sup>7</sup> As such, in this situation, the pathologist may decide  
6 to proceed with an external examination, X-ray and examination of the placenta and  
7 omit internal examination of the organs (Appendix A).

8  
9 The following protocol describes recommended practice when undertaking a full  
10 examination in this context.

- 11 • Whole body X-ray for gestational age assessment and malformation is recommended  
12 in all cases; it is mandatory for suspected skeletal dysplasia and where there are  
13 multiple developmental abnormalities. If available, this may be complemented by other  
14 imaging modalities, e.g. micro-computed tomography (micro-CT), ultrasound scan  
15 (USS), magnetic resonance imaging (MRI).<sup>8-11</sup>
- 16 • Photography of the fetus is mandatory in all cases and should be used to document  
17 external and internal abnormalities. Digital photography and secure storage should  
18 comply with local information governance standards.
- 19 • Routine measurements should be taken (body weight, crown–heel length, foot length.  
20 Consider taking crown–rump length, occipito-frontal circumference, inner and outer  
21 canthal measurements). Abdominal circumference has not been validated as a post-  
22 mortem measurement.
- 23 • Detailed external examination, including: nutritional status/soft tissue and muscle bulk,  
24 maceration, local/generalised oedema, pallor, meconium staining, dysmorphic  
25 features, evidence of disruption/trauma and iatrogenic lesions, assessment of patency  
26 of orifices (including choanae) and palatal fusion, limbs (positional abnormalities, skin  
27 webs), hands and feet and genitalia.<sup>12</sup> Recording of negative findings is not required  
28 unless clinically requested or relevant.
- 29 • Cases being submitted for MRI/USS/micro-CT examination should be examined by a  
30 pathologist and then transferred to appropriate imaging facilities before returning for  
31 further assessment, ideally with any available interim imaging reports. At this time,  
32 follow up with dissection-based autopsy (in line with parental consent) is appropriate,  
33 but may be omitted at the discretion of the examining pathologist in line with their

1 experience and expertise in these modalities. In practice, if the findings are discordant  
2 with the antenatal information, follow up dissection is recommended, where consent  
3 permits.

4 • Routine histological examination of macroscopically normal organs (in the absence of  
5 a clinical indication to sample the organ) shows low diagnostic low yield.<sup>7</sup> Histology of  
6 the placenta, membrane and cord have a relatively high yield and are mandatory.<sup>13,14</sup>

7 • Incisions on the body should be placed with due regard to the requirement for  
8 reconstruction. Standard incisions include typically T- or Y-shaped; an inverted Y-  
9 shaped incision of the lower abdominal wall can be considered for assessment of the  
10 internal lower abdominal wall. A bilateral paramedian incision to reflect the complete  
11 anterior body wall can also be considered.

12 • Detailed systematic examination of other internal organs, within the limitations of  
13 maceration and consent, including:

14 – umbilical arteries and vein

15 – in-situ examination of the heart and great vessels with sequential segmental  
16 analysis of malformations

17 – in-situ examination of thoracic and abdominal organs; consider removing in  
18 continuity to assess abnormal structures crossing diaphragm

19 – weights of internal organs (brain, heart, lungs, liver, kidneys, thymus, adrenals,  
20 spleen) and calculate organ to organ weight ratios (brain to liver, brain to thymus,  
21 lung to body weight, body weight to placenta weight)

22 – apply special dissection techniques where appropriate.

23  
24 *[Level of evidence – GPP.]*

## 25 **5.1 Central nervous system examination**

26 If the baby is otherwise non-dysmorphic and there is no suggestion of a neuro-muscular  
27 condition (i.e. there are no contractures, facial features are not suggestive of  
28 holoprosencephaly, etc.), there is little evidence of the benefit in examining the brain. If  
29 there is suspicion of a neuromuscular condition, even if the skull is collapsed, examination  
30 of the central nervous system should be considered and attempted if possible.

31

## 1 **5.2 Approaches to brain examination**

- 2 • Median posterior or transverse scalp incision
- 3 • Skull incisions to allow assessment of falx and venous sinuses
- 4 • Observation of brain maturation to assist gestational assessment
- 5 • Consider removal under water (or direct in formalin) and perhaps in dura especially
- 6 with marked autolysis: will permit weighing and assessment of gyral pattern
- 7 • Consider following external and macroscopic assessment to determine whether
- 8 histological examination is indicated
- 9 • Consider specialist neuropathologist review.

10  
11 *[Level of evidence – GPP.]*

## 12 **5.3 Placental examination**

13 Placental examination is an integral part of the perinatal post-mortem examination.  
14 Submission to pathology with the baby is mandatory; non-conformances should be  
15 monitored in line with local policies. Guidance for detailed examination of the placenta is  
16 given in the *Tissue pathway for examination of the placenta*.<sup>15</sup>

17 *[Level of evidence – B.]*

## 18 **6 Specific health and safety aspects**

19 The pathologist should be informed as part of the referral if there is a potential biohazard  
20 risk.

21 Autopsy practice using universal precautions will significantly protect against accidental  
22 transmission of infection, including HIV, SARS CoV-2 and other blood-borne viruses.

## 23 **7 Focused autopsy: limited by parental consent or by** 24 **a stepwise post-mortem examination**

25 Where consent for a full autopsy is not given, a focused examination may be of value  
26 within the limitations of the investigation. Forms of limited examination may include:

- 27 • autopsy limited to 1 or more body cavities or head

- 1 • external examination of the body with X-ray, photography and genetics (if indicated)
- 2 • placental examination only (with genetic testing if indicated)
- 3 • minimal invasive autopsy: external examination and imaging (CT, MRI, ultrasound
- 4 examination – if available) alone or with targeted biopsies of specific organs.<sup>16</sup>

5  
6 *[Level of evidence – B.]*

## 7 **8 Sampling at full post-mortem examination**

- 8 • Short-term retention of organs to allow fixation does not require specific consent,
- 9 provided they are reunited with the body before release for burial/cremation. Organ
- 10 and tissue retention should be dealt with in line with the parental consent form.
- 11 • The diagnostic yield for histology taken from macroscopically normal organs is low.
- 12 The extent of the examination is at the discretion of the pathologist and should be
- 13 interpreted in the clinical context of the case.
- 14 • A record of the samples taken should be kept and tissue blocks and slides should be
- 15 traceable within the laboratory, in line with the requirements of the HTA and the UK
- 16 Accreditation Service (ISO 15189).
- 17 • Microbiology: consider bacteriology and virology as clinically indicated.
- 18 • Genetic samples: the diagnostic yield of microarray, karyotype and quantitative
- 19 fluorescent PCR (QF-PCR) is low in the context of a morphologically normal fetus,
- 20 however, in a third or more pregnancy losses microarray and genetic testing is
- 21 indicated according to current guidelines. The current Genomic Laboratory Hub (GLH)
- 22 guideline should be followed by the fetal medicine multidisciplinary team (MDT)
- 23 collaborating with the pathologist. (Wales: All Wales Genomics Laboratory; Scotland:
- 24 Scottish Strategic Network for Genomic Medicine [SSNGM] laboratories; Northern
- 25 Ireland: Northern Ireland Genomics Medicine Centre [NIGMC].)

26  
27 *[Level of evidence B and C – in line with statutory obligations.]*

## 28 **9 Autopsy report**

29 Units may choose, if resources allow, to issue a provisional report giving details of the

30 macroscopic findings shortly after the examination of the body, followed by a final report

1 when all histology and other tests have been completed. Alternatively, only a single, final  
2 report may be produced.

3 The report should include the following sections, where performed:

- 4 • demographic and identification data
- 5 • details of autopsy consent and limitations
- 6 • body weight
- 7 • body measurements with relevant reference values
- 8 • list of main findings
- 9 • clinicopathological summary (final report)
- 10 • summary of clinical history
- 11 • systematic description of external and internal findings and placental examination
- 12 • organ weights with relevant reference values and ratios
- 13 • details of ancillary tests taken (and results in final report)
- 14 • histology (final report)
- 15 • list of histology tissue blocks and retained organs and tissues, if applicable (final  
16 report).

17  
18 *[Level of evidence – GPP.]*

## 19 **9.1 Clinicopathological summary**

20 The summary should include:

- 21 • an assessment of gestational age at death (comment on how the size relates to the  
22 gestational age established by the dating scan)
- 23 • in second trimester intrauterine death, the degree of maceration and likely timing and  
24 cause of death (if determined)
- 25 • in miscarriage, the likely cause of the miscarriage
- 26 • reference to previous losses/terminations of pregnancy, their outcome and relevance to  
27 the current pregnancy loss
- 28 • explicit statements regarding the presence/absence of malformation, and infection

- 1 • a discussion of the likely mechanism of death
- 2 • concordance or discordance of findings with the clinical history and prenatal testing (if  
3 appropriate)
- 4 • identification of those cases with an increased risk of recurrence (including growth  
5 restriction, maternal diabetes, genetic disease, maternal alloimmune conditions) and  
6 requirement/possibility of additional testing
- 7 • reference to previous losses/terminations of pregnancy, their outcome and relevance to  
8 the current pregnancy loss
- 9 • results of MDTs, such as the clinical genetics MDT and its outcome, including  
10 molecular genetic diagnosis. In these cases, an addendum report or reports would be  
11 appropriate.

12 *[Level of evidence – GPP.]*

## 13 **10 Coding**

14 The autopsy procedure and principal findings should be coded according to the SNOMED  
15 CT system using appropriate body structure, finding, disorder and morphologic  
16 abnormality codes for SNOMED CT or appropriate T (topographic) and M (morphologic)  
17 for older versions of SNOMED (local protocols should be followed).

18 Of note, SNOMED ceased to be licensed by the International Health Terminology  
19 Standards Development Organisation from 26 April 2017; the authors recognise that NHS  
20 England aspires to fully transition to SNOMED CT.

21 The requirement to enable SNOMED CT content in secondary care systems is yet to be  
22 fully achieved, although it is known that many providers have SNOMED CT-enabled EPR  
23 systems in place. SNOMED CT is used in many different healthcare settings  
24 internationally and is an NHS-approved fundamental standard (SCCI0034). SNOMED CT  
25 gives clinical IT systems a single shared language, making the exchange of information  
26 between systems easier, safer and more accurate. It contains all the clinical terms needed  
27 for the whole NHS, from procedures and symptoms through to clinical measurements,  
28 diagnoses, medications and pathological findings.

29 The [NHS Digital SNOMED CT UK browser](#) can be accessed for free.

30 A non-exhaustive list of autopsy-related SNOMED CT codes is provided in Appendix D.



## 1 **11 Criteria for audit**

2 The following standards are suggested criteria that might be used in periodic reviews to  
3 ensure a post-mortem examination report meets national standards. The phase of the  
4 autopsy examination (pre-analytical, analytical and post-analytical) assessed by the  
5 standard is included.

6 Supporting documentation:

- 7 • standards: supporting documentation was submitted with the body in 95% of cases  
8 [pre-analytical]. (NB: it is recommended that an autopsy should not be commenced in  
9 the absence of clinical information.)
- 10 • standards: 95% of submitted information is satisfactory, good or excellent [pre-  
11 analytical]
- 12 • standards: a correctly completed autopsy consent form, meeting national requirements  
13 is submitted with 95% of cases [pre-analytical]. (NB: an autopsy must not be  
14 commenced unless the pathologist has seen a physical copy of the consent form and it  
15 is correctly completed.)

16  
17 Autopsy report:

- 18 • standards: 100% of autopsy reports must include all of the sections detailed in section  
19 15, within the limits of parental consent and extent of the examination determined by  
20 the responsible consultant (above) [analytical]
- 21 • standards: in 100% of autopsy reports, the information documented is satisfactory,  
22 good or excellent [analytical]
- 23 • standards: in 100% of autopsy reports, the clinicopathological summary is clear and  
24 concise and, when appropriate, contains the information detailed above [analytical]
- 25 • standards: 80% of autopsy reports are completed within the turnaround times agreed  
26 with local clinical teams, excluding cases where turnaround time is compromised by  
27 testing outside of the control of the responsible consultant (e.g. genetic array,  
28 neuropathological examination) [post-analytical]
- 29 • standards: 100% of autopsy reports are communicated to referring centres using  
30 secure email (e.g. nhs.net email) or encrypted email [post-analytical]

- 1 • standards: 100% of autopsy cases are coded appropriately according to local  
2 guidelines [post-analytical].

3  
4 For reference, the NHS specifications (from the 2013/2014 standard contract for perinatal  
5 pathology<sup>17</sup>) are as follows:

6 *60% of final reports for routine post-mortem examination will be issued to referrers*  
7 *within 42 days of examination and 90% should be issued within 56 days. This will*  
8 *exclude those cases in which there may be a specialist referral opinion required (e.g.*  
9 *neuropathology) or very complex metabolic or genetic testing required.*

10 These are mandatory contractual requirements of units commissioned to provide perinatal  
11 pathology services and are important measures of service quality and outcomes. The  
12 authors recognise that paediatric and perinatal pathology services have ongoing staffing  
13 and associated operational challenges and where services are shorthanded or otherwise  
14 under provisioned, or are providing mutual aid to other units, specific audit targets will be  
15 agreed between commissioners and clinical teams, but with the view that all units should  
16 be working towards the standards set out in the service specification.


17 The authors recognise that many units are inadequately staffed with either pathologists or  
18 APTs. Failure to achieve targets is unlikely to reflect the performance of individual  
19 pathologists but may indicate the need for a managerial review of local systems in place to  
20 ensure timely reports, and measures such as mutual aid should be considered. Where  
21 services are shorthanded or otherwise under provisioned, temporary audit targets should  
22 be agreed with clinical teams and outsourcing of reporting or other measures should be  
23 considered.

## 12 References

1. Faye-Petersen OM, Guinn DA, Wenstrom KD. Value of perinatal autopsy. *Obstet Gynecol* 1999; 94:915–920.
2. Gordijn SJ, Erwich JJHM, Khong TY. Value of the perinatal autopsy: critique. *Pediatr Dev Pathol* 2002;5:480–488.
3. Human Tissue Authority. *Sands guide for consent takers: seeking consent for the post mortem examination of a baby*. Accessed May 2023. Available at: [www.hta.gov.uk/guidance-professionals/regulated-sectors/post-mortem/post-mortem-model-consent-forms/sands](http://www.hta.gov.uk/guidance-professionals/regulated-sectors/post-mortem/post-mortem-model-consent-forms/sands)
4. Human Tissue Authority. *Human Tissue Authority Codes of Practice*. Accessed May 2023. Available at: [www.hta.gov.uk/codes](http://www.hta.gov.uk/codes)
5. Acts of Scottish Parliament. *Human Tissue (Scotland) Act 2006*. Accessed February 2024. Available at: [www.legislation.gov.uk/asp/2006/4/contents](http://www.legislation.gov.uk/asp/2006/4/contents)
6. NHS England. *Interim clinical commissioning urgent policy statement: Perinatal post-mortem investigation of fetal and neonatal deaths (England, Scotland and Wales)*. Accessed May 2023. Available at: [www.england.nhs.uk/publication/perinatal-post-mortem-investigation-of-fetal-and-neonatal-deaths-england-scotland-and-wales/](http://www.england.nhs.uk/publication/perinatal-post-mortem-investigation-of-fetal-and-neonatal-deaths-england-scotland-and-wales/)
7. Lewis C, Hutchinson JC, Riddington M, Hill M, Arthurs OJ, Fisher J *et al*. Minimally invasive autopsy for fetuses and children based on a combination of post-mortem MRI and endoscopic examination: a feasibility study. *Health Technol Assess* 2019;23:1–104.
8. Hutchinson JC, Kang X, Shelmerdine SC, Segers V, Lombardi CM, Cannie MM *et al*. Postmortem microfocus computed tomography for early gestation fetuses: a validation study against conventional autopsy. *Am J Obstet Gynecol* 2018;21:445.
9. Shelmerdine SC, Simcock IC, Hutchinson JC, Guy A, Ashworth MT, Sebire NJ *et al*. Postmortem microfocus computed tomography for noninvasive autopsies: experience in >250 human fetuses. *Am J Obstet Gynecol* 2021;224:103.
10. Shelmerdine S, Langan D, Sebire NJ, Arthurs O. Diagnostic accuracy of perinatal post-mortem ultrasound (PMUS): a systematic review. *BMJ Paediatr Open* 2019;11:566.

11. Thayyil S, Sebire NJ, Chitty LS, Wade A, Chong W, Olsen O *et al.* Post-mortem MRI versus conventional autopsy in fetuses and children: a prospective validation study. *Lancet* 2013;20:223–233.
12. Ernst LM. A pathologist's perspective on the perinatal autopsy. *Semin Perinatol* 2015;55–63.
13. Man J, Hutchinson JC, Heazell AE, Ashworth M, Jeffrey I, Sebire NJ. Stillbirth and intrauterine fetal death: role of routine histopathological placental findings to determine cause of death. *Ultrasound Obstet Gynecol* 2016;5:579–584.
14. Heazell AEP, Martindale EA. Can post-mortem examination of the placenta help determine the cause of stillbirth? *J Obstet Gynaecol* 2009;29:225–228.
15. The Royal College of Pathologists. *Tissue pathway for histopathological examination of the placenta*; 2022. Accessed May 2023. Available at: [www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html](http://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html)
16. Shelmerdine SC, Arthurs OJ, Gilpin I, Norman W, Jones R, Taylor AM *et al.* Is traditional perinatal autopsy needed after detailed fetal ultrasound and post-mortem MRI? *Prenat Diagn* 2019;39:818–829.
17. NHS England. *2013/14 NHS Standard Contract for Perinatal Pathology*. Accessed May 2023. Available at: [www.england.nhs.uk/wp-content/uploads/2013/06/e12-perinatal-path.pdf](http://www.england.nhs.uk/wp-content/uploads/2013/06/e12-perinatal-path.pdf)

# Appendix A Suggested flowchart of a triage approach



## Appendix B Sample autopsy request form

### CLINICAL INFORMATION FOR FETAL / PERINATAL POST MORTEM

Mother (sticker if available)
Family Name:.....
First Name:.....
D.o.B.: / /
Reg No.....

Fetus / Infant (sticker if available)
Family Name:.....
First Name:.....
D.o.B.: / /      D.o.D: / /
Reg No.....

Please carefully complete this form. Any missing information could potentially delay or alter the findings.

Parts 1, 2 and 3 ALL require completion for EVERY referral made.

REFERRING HOSPITAL: \_\_\_\_\_ Ward: \_\_\_\_\_

HOSPITAL OF BIRTH (if different): \_\_\_\_\_

(Please include history / notes from previous hospitals)

CONSULTANT OBSTETRICIAN: \_\_\_\_\_

CONSULTANT PAEDIATRICIAN: \_\_\_\_\_

#### Part 1. MOTHER'S DETAILS

(ALL fields for this section are MANDATORY for ALL requests please)

Ethnic origin: \_\_\_\_\_ Father's ethnic origin (if known) \_\_\_\_\_

Consanguinity between parents? Y/N      Blood group: \_\_\_\_\_

Maternal height: _____ cm	Booking weight: _____ kg	BMI: _____
---------------------------	--------------------------	------------

#### Obstetric History:

##### PREVIOUS PREGNANCIES

	Date	Gestation	Delivery	Sex	Outcome
1.					
2.					
3.					
4.					
5.					
6.					
7.					

Were there any complications with any previous pregnancies (this current pregnancy excluded)?\*  
Yes / No / Not known - if yes, specify

\*Further space for writing is provided on p4 of this form.

**This form consists of 4 pages. All require your attention.**

Please carefully complete this form. Any missing information could potentially delay or alter the findings.

**Part 2. CURRENT PREGNANCY DETAILS**

(ALL fields for this section are MANDATORY for ALL requests please)

Booked/Unbooked LMP : \_\_\_\_\_ EDD: \_\_\_\_\_

Gestation: by dates: \_\_\_\_\_/40 by scan: \_\_\_\_\_/40 weeks

Is there any relevant past medical history? (If yes, what?) \_\_\_\_\_

Were there any abnormal screening results? (If yes, what? Fetal growth issues and uterine artery Doppler results?) \_\_\_\_\_

Medications (if any): \_\_\_\_\_

USS findings (please send report if abnormal):

	Date	Indication (e.g. dating / anomaly, etc.)	Gestation	Findings (please include report if abnormal)
1.				
2.				
3.				
4.				

Antenatal diagnostic procedures (please include results if available / known):  
(e.g. CVS sampling or other invasive techniques / fetal MRI)

\_\_\_\_\_

Additional antenatal history:

Was this a twin pregnancy?	Y/N	If so, MCDA/ MCMA/ DCDA?
Any history of reduced fetal movements?	Y/N	If so, how many episodes for how long?
Was there antenatal bleeding?	Y/N	If so, when and how much?
Was there hypertension?	Y/N	BP = mmHg
Was there pre-eclampsia?	Y/N	BP = mmHg
Was there anaemia?	Y/N	

Is there anything else of relevance regarding the pregnancy that you would like to tell the pathologist? Labour and delivery details are detailed in the following section\*.

\*Further space for writing is provided on p4 of this form.

N.B. Would this PM examination be classed as an infection risk to relevant staff? Y/N

**This form consists of 4 pages. All require your attention.**

Please carefully complete this form. Any missing information could potentially delay or alter the findings.

**Part 3: LABOUR & DELIVERY DETAILS**

Have you completely filled part 1 & 2? Any missing information can alter the findings.

- 1) Was this a TOP? Y/N
- a) If TOP – Feticide Y/N If so, method and date of feticide:
- 2) Was this a miscarriage (i.e. pregnancy loss <24 weeks' gestation)? Y/N
- 3) Was this an IUD > 24 weeks' gestation (i.e. macerated stillbirth)? Y/N
- If so, when was the last documented evidence of fetal / infant viability / fetal heart beat?
- 4) Was this an intrapartum or neonatal death (i.e. fresh stillbirth / live birth)? Y/N
- What was the presenting part? Vertex / Breech / Other
- b) Rupture of membranes: date \_\_\_\_\_ time \_\_\_\_\_ Augmentation (Syntocinon): Y/N
- c) 1st stage \_\_h \_\_min 2nd : \_\_h \_\_min
- d) Abnormal fetal monitoring or suspected fetal compromise: Y/N If yes, please specify signs:

e) DELIVERY: Spont. / Assisted (forceps / ventouse) / CS (elective / emergency). Date \_\_\_\_\_  
Time \_\_\_\_\_

f) Apgars: 1st min \_\_\_\_\_ 5th min \_\_\_\_\_ 10th min \_\_\_\_\_

Did labour commence spontaneously / did it require induction?

Date of induction, if applicable:

Liquor: Normal / reduced volume / increased volume.

Was there antepartum haemorrhage?

Date of delivery:

Abnormal liquor colour?

Was there maternal pyrexia, concerns re: maternal infection?

The infant or fetus			Any notable abnormalities in the fetus / infant at time of delivery*:
Male ♂	Female ♀	Indeterminate	
Birth Weight (g):			

\*Further space is provided for writing on p4 of this form.

**Part 4: For LIVEBORN infants ONLY (i.e. Neonatal deaths):**

Have you completely filled parts 1, 2 & 3?

RESUSCITATION procedures employed:

Surfactant: Y/N

NEONATAL PROBLEMS & PROCEDURES:

**BRIEF SUMMARY OF LATER SYMPTOMS / TREATMENTS AND MAJOR INVESTIGATIONS**  
(including CPAP / ventilation, IV therapy, fits, episodes of collapse, pneumonia, pneumothorax, bleeding problems, type of feeding, etc.)

\*Further space for writing is provided on p4 of this form.

**Attention please:** If this was a complex course, please consider sending YOUR summary and interpretation of events. Sending photocopies of the notes or the complete set of notes may be acceptable, but not advisable for optimal practice.

SUSPECTED CAUSE(S) OF DEATH:

DEATH REGISTERED AS (if applicable):

ANY OTHER RELEVANT INFORMATION / SPECIAL POINTS TO BE NOTED AT POST MORTEM:

\*Further space for writing is provided on p4 of this form.

**This form consists of 4 pages. All require your attention.**



Please carefully complete this form. Any missing information could potentially delay or alter the findings.

Please do not hesitate to contact us should you have any queries regarding the completion of this form.

Person completing form: \_\_\_\_\_ Contact number / bleep  
No \_\_\_\_\_

(Please PRINT)

Copy of report to be sent to:

Consultant obstetrician: (Mr/ Ms/ Mrs/ Dr) \_\_\_\_\_ and/or  
(Please PRINT)

Consultant paediatrician: \_\_\_\_\_  
(Please PRINT)

Thank you for carefully completing all relevant parts of this form. Parts 1, 2 and 3 all require your attention please.

May we remind you that any missing information could potentially delay or alter the findings.

Notes for any further relevant information and short narrative of the clinical synopsis:

---

---

---

---

---

---

---

---

**ALL BABIES AND PLACENTAS SHOULD BE SENT FRESH IN LEAKPROOF, OPAQUE CONTAINERS UNLESS THERE IS AN INFECTIOUS HAZARD** (in this case phone to discuss whether the specimen should be fixed in 10% formalin before transportation)

**IT IS ESSENTIAL TO SEND THE PLACENTA WITH A FETUS / INFANT.**

**This form consists of 4 pages. All require your attention.**

## Appendix C Autopsy-related SNOMED CT codes

The following codes are suggested for centres with SNOMED CT capabilities. Local coding procedures should be followed where SNOMED CT has yet to be implemented. The suggested lists below are not exhaustive but highlight examples of codes that could be used. The [NHS Digital SNOMED CT UK browser](#) can be accessed for free.

### General autopsy codes

29240004		Autopsy examination (procedure)
702692002		Coroner's autopsy (procedure)
5785009		Forensic autopsy (procedure)
430339001		Pediatric autopsy (procedure)
308375000		Report for Procurator Fiscal (record artifact)

### Specimen codes

309502007		Fetus specimen (specimen)
725957005		Formalin-fixed placenta tissue specimen (specimen)

### Post-mortem imaging

717193008		Cone beam computed tomography (procedure)
699581005		Post mortem magnetic resonance imaging (procedure)
713599004		Post mortem ultrasonography (procedure)

### Fetal findings

85811006		Autolysis (morphologic abnormality)
248200007		Dysmorphic facies (finding)
87309006		Death of unknown cause (event)
22033007		Fetal growth retardation (disorder)
289448000		Fetus normal (finding)
198901003		Macerated fetus (disorder)
85728002		Morphologic description only (finding)

723745006 | Morphological description only, with differential diagnosis (finding)  
41962002 | Oligohydramnios sequence (disorder)

## **Placental findings**

4532008 | Acute inflammation (morphologic abnormality)  
84499006 | Chronic inflammation (morphologic abnormality)  
396343006 | Funisitis (disorder)  
65396000 | Histiocytic infiltrate (morphologic abnormality)  
125563001 | Hyalinized fibrosis (morphologic abnormality)  
55641003 | Infarct (morphologic abnormality)  
73728008 | Maturation acceleration (morphologic abnormality)  
50353005 | Maturation deceleration (morphologic abnormality)  
309162003 | Normal histology findings (finding)  
415105001 | Placental abruption (disorder)  
268585006 | Placental infarct (disorder)  
237292005 | Placental insufficiency (disorder)  
448485001 | Specimen satisfactory for evaluation but limited by cellular degeneration (finding)  
27696007 | True knot of umbilical cord (disorder)  
75798003 | Twin dichorionic diamniotic placenta (disorder)  
83787007 | Twin monochorionic diamniotic placenta (disorder)  
388604008 | Villitis (disorder)  
1155707008 | High histologic grade  
1155708003 | Low histologic grade (qualifier value)  
1155705000 | Histologic grade cannot be assessed (qualifier value)

## Appendix D Summary table – Explanation of grades of evidence

(modified from Palmer K *et al. BMJ* 2008; 337:1832)

Grade (level) of evidence	Nature of evidence
Grade A	<p>At least 1 high-quality meta-analysis, systematic review of randomised controlled trials or a randomised controlled trial with a very low risk of bias and directly attributable to the target population</p> <p>or</p> <p>A body of evidence demonstrating consistency of results and comprising mainly well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias, directly applicable to the target cancer type.</p>
Grade B	<p>A body of evidence demonstrating consistency of results and comprising mainly high-quality systematic reviews of case-control or cohort studies and high-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relation is causal and which are directly applicable to the target population</p> <p>or</p> <p>Extrapolation evidence from studies described in A.</p>
Grade C	<p>A body of evidence demonstrating consistency of results and including well-conducted case-control or cohort studies and high-quality case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relation is causal and which are directly applicable to the target population</p> <p>or</p> <p>Extrapolation evidence from studies described in B.</p>
Grade D	<p>Non-analytic studies such as case reports, case series or expert opinion</p> <p>or</p> <p>Extrapolation evidence from studies described in C.</p>
Good practice point (GPP)	<p>Recommended best practice based on the clinical experience of the authors of the writing group.</p>

## Appendix E AGREE II guideline monitoring sheet

The guidelines of the Royal College of Pathologists comply with the AGREE II standards for good quality clinical guidelines. The sections of this guideline that indicate compliance with each of the AGREE II standards are indicated in the table.

<b>AGREE standard</b>	<b>Section of guideline</b>
<b>Scope and purpose</b>	
1 The overall objective(s) of the guideline is (are) specifically described	Introduction
2 The health question(s) covered by the guideline is (are) specifically described	Introduction
3 The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described	Foreword, Introduction
<b>Stakeholder involvement</b>	
4 The guideline development group includes individuals from all the relevant professional groups	Foreword
5 The views and preferences of the target population (patients, public, etc.) have been sought	Foreword
6 The target users of the guideline are clearly defined	Introduction
<b>Rigour of development</b>	
7 Systematic methods were used to search for evidence	Foreword
8 The criteria for selecting the evidence are clearly described	Foreword
9 The strengths and limitations of the body of evidence are clearly described	Foreword
10 The methods for formulating the recommendations are clearly described	Foreword
11 The health benefits, side effects and risks have been considered in formulating the recommendations	N/A
12 There is an explicit link between the recommendations and the supporting evidence	Throughout
13 The guideline has been externally reviewed by experts prior to its publication	Foreword
14 A procedure for updating the guideline is provided	Foreword
<b>Clarity of presentation</b>	
15 The recommendations are specific and unambiguous	Throughout
16 The different options for management of the condition or health issue are clearly presented	Throughout
17 Key recommendations are easily identifiable	Throughout

<b>Applicability</b>	
18 The guideline describes facilitators and barriers to its application	Foreword
19 The guideline provides advice and/or tools on how the recommendations can be put into practice	All appendices
20 The potential resource implications of applying the recommendations have been considered	Foreword
21 The guideline presents monitoring and/or auditing criteria	11
<b>Editorial independence</b>	
22 The views of the funding body have not influenced the content of the guideline	Foreword
23 Competing interest of guideline development group members have been recorded and addressed	Foreword

DRAFT